Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Current Colorectal Cancer Reports
Published in: Current Colorectal Cancer Reports 4/2014

01-12-2014 | Molecular Biology (S Anant, Section Editor)

Targeting Notch Signaling in Colorectal Cancer

Authors: Suman Suman, Trinath P. Das, Murali K. Ankem, Chendil Damodaran

Published in: Current Colorectal Cancer Reports | Issue 4/2014

Login to get access

Abstract

The activation of Notch signaling is implicated in tumorigenesis in the colon due to the induction of pro-survival signaling in colonic epithelial cells. Chemoresistance is a major obstacle for treatment and for the complete eradication of colorectal cancer (CRC); hence, the inhibition of Notch is an attractive target for CRC and several groups are working to identify small molecules or monoclonal antibodies that inhibit Notch or its downstream events; however, toxicity profiles in normal cells and organs often impede the clinical translation of these molecules. Dietary agents have gained momentum for targeting several pro-survival signaling cascades, and recent studies demonstrated that agents that inhibit Notch signaling result in growth inhibition in preclinical models of CRC. In this review, we focus on the importance of Notch as a preventive and therapeutic target for colon cancer and on the effect of WA on this signaling pathway in the context of colon cancer.
Literature
1.
2.
3.
Siegel R, Desantis C, Jemal A. Colorectal cancer statistics, 2014. CA Cancer J Clin. 2014;64(2):104–17.PubMedCrossRef
4.
Wu WK et al. Dysregulation and crosstalk of cellular signaling pathways in colon carcinogenesis. Crit Rev Oncol Hematol. 2013;86(3):251–77.PubMedCrossRef
5.•
Noah TK, Shroyer NF. Notch in the intestine: regulation of homeostasis and pathogenesis. Annu Rev Physiol. 2013;75:263–88. This article describe the role of Notch in intestinal homeostasis and colorectal cancer.PubMedCrossRef
6.
Qiao L, Wong BC. Role of Notch signaling in colorectal cancer. Carcinogenesis. 2009;30(12):1979–86.PubMedCrossRef
7.
Barolo S, Posakony JW. Three habits of highly effective signaling pathways: principles of transcriptional control by developmental cell signaling. Genes Dev. 2002;16(10):1167–81.PubMedCrossRef
8.
9.
Meng RD et al. gamma-Secretase inhibitors abrogate oxaliplatin-induced activation of the Notch-1 signaling pathway in colon cancer cells resulting in enhanced chemosensitivity. Cancer Res. 2009;69(2):573–82.PubMedPubMedCentralCrossRef
10.
Blaumueller CM et al. Intracellular cleavage of Notch leads to a heterodimeric receptor on the plasma membrane. Cell. 1997;90(2):281–91.PubMedCrossRef
11.
Fre S et al. Notch signals control the fate of immature progenitor cells in the intestine. Nature. 2005;435(7044):964–8.PubMedCrossRef
12.
Pellegrinet L et al. Dll1- and dll4-mediated notch signaling are required for homeostasis of intestinal stem cells. Gastroenterology. 2011;140(4):1230–40. e1-7.PubMedPubMedCentralCrossRef
13.
14.
Zheng H et al. KLF4 gene expression is inhibited by the notch signaling pathway that controls goblet cell differentiation in mouse gastrointestinal tract. Am J Physiol Gastrointest Liver Physiol. 2009;296(3):G490–8.PubMedPubMedCentralCrossRef
15.
Riccio O et al. Loss of intestinal crypt progenitor cells owing to inactivation of both Notch1 and Notch2 is accompanied by depression of CDK inhibitors p27Kip1 and p57Kip2. EMBO Rep. 2008;9(4):377–83.PubMedPubMedCentralCrossRef
16.
Schroder N, Gossler A. Expression of Notch pathway components in fetal and adult mouse small intestine. Gene Expr Patterns. 2002;2(3–4):247–50.PubMedCrossRef
17.
Sander GR, Powell BC. Expression of notch receptors and ligands in the adult gut. J Histochem Cytochem. 2004;52(4):509–16.PubMedCrossRef
18.
VanDussen KL et al. Notch signaling modulates proliferation and differentiation of intestinal crypt base columnar stem cells. Development. 2012;139(3):488–97.PubMedPubMedCentralCrossRef
19.
20.
21.
Kosinski C et al. Gene expression patterns of human colon tops and basal crypts and BMP antagonists as intestinal stem cell niche factors. Proc Natl Acad Sci U S A. 2007;104(39):15418–23.PubMedPubMedCentralCrossRef
22.
van Es JH et al. Notch/gamma-secretase inhibition turns proliferative cells in intestinal crypts and adenomas into goblet cells. Nature. 2005;435(7044):959–63.PubMedCrossRef
23.
24.
Fre S et al. Notch and Wnt signals cooperatively control cell proliferation and tumorigenesis in the intestine. Proc Natl Acad Sci U S A. 2009;106(15):6309–14.PubMedPubMedCentralCrossRef
25.
Katoh M, Katoh M. Notch signaling in gastrointestinal tract (review). Int J Oncol. 2007;30(1):247–51.PubMed
26.
Shroyer NF et al. Intestine-specific ablation of mouse atonal homolog 1 (Math1) reveals a role in cellular homeostasis. Gastroenterology. 2007;132(7):2478–88.PubMedCrossRef
27.
Yang Q et al. Requirement of Math1 for secretory cell lineage commitment in the mouse intestine. Science. 2001;294(5549):2155–8.PubMedCrossRef
28.
Zheng X et al. Suppression of hath1 gene expression directly regulated by hes1 via notch signaling is associated with goblet cell depletion in ulcerative colitis. Inflamm Bowel Dis. 2011;17(11):2251–60.PubMedCrossRef
29.
Schroeter EH, Kisslinger JA, Kopan R. Notch-1 signalling requires ligand-induced proteolytic release of intracellular domain. Nature. 1998;393(6683):382–6.PubMedCrossRef
30.
Yin L, Velazquez OC, Liu ZJ. Notch signaling: emerging molecular targets for cancer therapy. Biochem Pharmacol. 2010;80(5):690–701.PubMedCrossRef
31.
Ellisen LW et al. TAN-1, the human homolog of the Drosophila notch gene, is broken by chromosomal translocations in T lymphoblastic neoplasms. Cell. 1991;66(4):649–61.PubMedCrossRef
32.
Pear WS et al. Exclusive development of T cell neoplasms in mice transplanted with bone marrow expressing activated Notch alleles. J Exp Med. 1996;183(5):2283–91.PubMedCrossRef
33.
Kimura K et al. Activation of Notch signaling in tumorigenesis of experimental pancreatic cancer induced by dimethylbenzanthracene in mice. Cancer Sci. 2007;98(2):155–62.PubMedCrossRef
34.
Wang Z et al. Down-regulation of notch-1 inhibits invasion by inactivation of nuclear factor-kappaB, vascular endothelial growth factor, and matrix metalloproteinase-9 in pancreatic cancer cells. Cancer Res. 2006;66(5):2778–84.PubMedCrossRef
35.
Mao J et al. ShRNA targeting Notch1 sensitizes breast cancer stem cell to paclitaxel. Int J Biochem Cell Biol. 2013;45(6):1064–73.PubMedCrossRef
36.
Reedijk M et al. High-level coexpression of JAG1 and NOTCH1 is observed in human breast cancer and is associated with poor overall survival. Cancer Res. 2005;65(18):8530–7.PubMedCrossRef
37.
Suman S, Das TP, Damodaran C. Silencing NOTCH signaling causes growth arrest in both breast cancer stem cells and breast cancer cells. Br J Cancer. 2013;109(10):2587–96.PubMedCrossRef
38.
Santagata S et al. JAGGED1 expression is associated with prostate cancer metastasis and recurrence. Cancer Res. 2004;64(19):6854–7.PubMedCrossRef
39.
Marignol L. Targeting notch in prostate cancer-combination is the key. Nat Rev Urol. 2014;11(7):419.PubMedCrossRef
40.
Kwon OJ et al. Increased Notch signalling inhibits anoikis and stimulates proliferation of prostate luminal epithelial cells. Nat Commun. 2014;5:4416.PubMed
41.
Gao J et al. Expression of Jagged1 and its association with hepatitis B virus X protein in hepatocellular carcinoma. Biochem Biophys Res Commun. 2007;356(2):341–7.PubMedCrossRef
42.
Tripathi R et al. Clinical impact of de-regulated Notch-1 and Notch-3 in the development and progression of HPV-associated different histological subtypes of precancerous and cancerous lesions of human uterine cervix. PLoS One. 2014;9(6):e98642.PubMedPubMedCentralCrossRef
43.
Ramdass B et al. Coexpression of Notch1 and NF-kappaB signaling pathway components in human cervical cancer progression. Gynecol Oncol. 2007;104(2):352–61.PubMedCrossRef
44.
Curry CL et al. Notch inhibition in Kaposi’s sarcoma tumor cells leads to mitotic catastrophe through nuclear factor-kappaB signaling. Mol Cancer Ther. 2007;6(7):1983–92.PubMedCrossRef
45.
Konishi J et al. Gamma-secretase inhibitor prevents Notch3 activation and reduces proliferation in human lung cancers. Cancer Res. 2007;67(17):8051–7.PubMedCrossRef
46.
Wang H et al. The expression of VEGF and Dll4/Notch pathway molecules in ovarian cancer. Clin Chim Acta. 2014;436C:243–8.CrossRef
47.
Jundt F et al. Activated Notch1 signaling promotes tumor cell proliferation and survival in Hodgkin and anaplastic large cell lymphoma. Blood. 2002;99(9):3398–403.PubMedCrossRef
48.
Sjolund J et al. Suppression of renal cell carcinoma growth by inhibition of Notch signaling in vitro and in vivo. J Clin Invest. 2008;118(1):217–28.PubMedPubMedCentralCrossRef
49.
Ozawa T et al. Nuclear Notch3 expression is associated with tumor recurrence in patients with stage II and III colorectal cancer. Ann Surg Oncol. 2014;21(8):2650–8.PubMedCrossRef
50.
Dai Y et al. Silencing of Jagged1 inhibits cell growth and invasion in colorectal cancer. Cell Death Dis. 2014;5:e1170.PubMedCrossRef
51.
Farnie G et al. Novel cell culture technique for primary ductal carcinoma in situ: role of Notch and epidermal growth factor receptor signaling pathways. J Natl Cancer Inst. 2007;99(8):616–27.PubMedCrossRef
52.
Wong GT et al. Chronic treatment with the gamma-secretase inhibitor LY-411,575 inhibits beta-amyloid peptide production and alters lymphopoiesis and intestinal cell differentiation. J Biol Chem. 2004;279(13):12876–82.PubMedCrossRef
53.
Milano J et al. Modulation of notch processing by gamma-secretase inhibitors causes intestinal goblet cell metaplasia and induction of genes known to specify gut secretory lineage differentiation. Toxicol Sci. 2004;82(1):341–58.PubMedCrossRef
54.
Searfoss GH et al. Adipsin, a biomarker of gastrointestinal toxicity mediated by a functional gamma-secretase inhibitor. J Biol Chem. 2003;278(46):46107–16.PubMedCrossRef
55.
Veenendaal LM et al. Differential Notch and TGFbeta signaling in primary colorectal tumors and their corresponding metastases. Cell Oncol. 2008;30(1):1–11.PubMed
56.
Rodilla V et al. Jagged1 is the pathological link between Wnt and Notch pathways in colorectal cancer. Proc Natl Acad Sci U S A. 2009;106(15):6315–20.PubMedPubMedCentralCrossRef
57.•
Espinoza I, Miele L. Notch inhibitors for cancer treatment. Pharmacol Ther. 2013;139(2):95–110. This review article describes the role of Notch signaling and apporoaches inhibit this signaling in various cancers.PubMedPubMedCentralCrossRef
58.
Hayashi I et al. Neutralization of the gamma-secretase activity by monoclonal antibody against extracellular domain of nicastrin. Oncogene. 2012;31(6):787–98.PubMedPubMedCentralCrossRef
59.
Funahashi Y et al. A notch1 ectodomain construct inhibits endothelial notch signaling, tumor growth, and angiogenesis. Cancer Res. 2008;68(12):4727–35.PubMedPubMedCentralCrossRef
60.
Singh A et al. GSI promotes vincristine-induced apoptosis by enhancing multi-polar spindle formation. Cell Cycle. 2014;13(1):157–66.PubMedCrossRef
61.
Akiyoshi T et al. Gamma-secretase inhibitors enhance taxane-induced mitotic arrest and apoptosis in colon cancer cells. Gastroenterology. 2008;134(1):131–44.PubMedCrossRef
62.••
Takebe N, Nguyen D, Yang SX. Targeting notch signaling pathway in cancer: clinical development advances and challenges. Pharmacol Ther. 2014;141(2):140–9. This recent review article describes the role of Notch signaling in cancer as well as the agents in use to target Notch signaling in different cancer types.PubMedCrossRef
63.••
Timme CR, Gruidl M, Yeatman TJ. Gamma-secretase inhibition attenuates oxaliplatin-induced apoptosis through increased Mcl-1 and/or Bcl-xL in human colon cancer cells. Apoptosis. 2013;18(10):1163–74. It is a interesting study where authors have shown gamma-secretase inhibition resulted in decrease in oxaliplatin-induced apoptosis. This study warrants caution while treating colon cancer with the combination of GSIs and chemotherapy.PubMedCrossRef
64.
Herszenyi L et al. Chemoprevention of colorectal cancer: feasibility in everyday practice? Eur J Cancer Prev. 2008;17(6):502–14.PubMedCrossRef
65.
Cooper K et al. Chemoprevention of colorectal cancer: systematic review and economic evaluation. Health Technol Assess. 2010;14(32):1–206.
66.
Gwyn K, Sinicrope FA. Chemoprevention of colorectal cancer. Am J Gastroenterol. 2002;97(1):13–21.PubMedCrossRef
67.
68.
Vadodkar AS et al. Chemoprevention of breast cancer by dietary compounds. Anticancer Agents Med Chem. 2012;12(10):1185–202.PubMedCrossRef
69.
Mishra LC, Singh BB, Dagenais S. Scientific basis for the therapeutic use of Withania somnifera (Ashwagandha): a review. Altern Med Rev. 2000;5(4):334–46.PubMed
70.
Malik F et al. A standardized root extract of Withania somnifera and its major constituent withanolide-A elicit humoral and cell-mediated immune responses by up regulation of Th1-dominant polarization in BALB/c mice. Life Sci. 2007;80(16):1525–38.PubMedCrossRef
71.
Malik F et al. Reactive oxygen species generation and mitochondrial dysfunction in the apoptotic cell death of human myeloid leukemia HL-60 cells by a dietary compound Withaferin A with concomitant protection by N-acetyl cysteine. Apoptosis. 2007;12(11):2115–33.PubMedCrossRef
72.
Malik F et al. Immune modulation and apoptosis induction: Two sides of antitumoural activity of a standardised herbal formulation of Withania somnifera. Eur J Cancer. 2009;45(8):1494–509.PubMedCrossRef
73.
Winters M. Ancient medicine, modern use: Withania somnifera and its potential role in integrative oncology. Altern Med Rev. 2006;11(4):269–77.PubMed
74.••
Vyas AR, Singh SV. Molecular targets and mechanisms of cancer prevention and treatment by withaferin a, a naturally occurring steroidal lactone. AAPS J. 2014;16(1):1–10. The authors have discussed the in vivo potential and molecular targets of WA contributing to its anticancer effects.PubMedPubMedCentralCrossRef
75.
Mirjalili MH et al. Steroidal lactones from Withania somnifera, an ancient plant for novel medicine. Molecules. 2009;14(7):2373–93.PubMedCrossRef
76.
Bhattacharya SK, Satyan KS, Ghosal S. Antioxidant activity of glycowithanolides from Withania somnifera. Indian J Exp Biol. 1997;35(3):236–9.PubMed
77.
Kaileh M et al. Withaferin a strongly elicits IkappaB kinase beta hyperphosphorylation concomitant with potent inhibition of its kinase activity. J Biol Chem. 2007;282(7):4253–64.PubMedCrossRef
78.
Jayaprakasam B et al. Growth inhibition of human tumor cell lines by withanolides from Withania somnifera leaves. Life Sci. 2003;74(1):125–32.PubMedCrossRef
79.
Mohan R et al. Withaferin A is a potent inhibitor of angiogenesis. Angiogenesis. 2004;7(2):115–22.PubMedCrossRef
80.
Bhattacharya SK et al. Effect of Withania somnifera glycowithanolides on a rat model of tardive dyskinesia. Phytomedicine. 2002;9(2):167–70.PubMedCrossRef
81.
Chowdhury K, Neogy RK. Mode of action of Withaferin A and Withanolide D. Biochem Pharmacol. 1975;24(8):919–20.PubMedCrossRef
82.
Sabina PE, Chandel S, Raool KM. Evaluation of analgesic, antipyretic and ulcerogenice effect of Withaferin A. Int J Integr Biol. 2009;6(2):52–6.
83.
Lahat G et al. Vimentin is a novel anti-cancer therapeutic target; insights from in vitro and in vivo mice xenograft studies. PLoS One. 2010;5(4):e10105.PubMedPubMedCentralCrossRef
84.
85.
Srinivasan S et al. Par-4-dependent apoptosis by the dietary compound Withaferin A in prostate cancer cells. Cancer Res. 2007;67(1):246–53.PubMedCrossRef
86.
Roy RV et al. Withaferin A, a steroidal lactone from Withania somnifera, induces mitotic catastrophe and growth arrest in prostate cancer cells. J Nat Prod. 2013;76(10):1909–15.PubMedPubMedCentralCrossRef
87.•
Lee J, Sehrawat A, Singh SV. Withaferin A causes activation of Notch2 and Notch4 in human breast cancer cells. Breast Cancer Res Treat. 2012;136(1):45–56. Authors have shown the effect of WA in breast cancer cells. They showed activation of Notch 2,4 and inactivation of Notch1 by WA. Notch 2 and Notch4 knockdown augmented WA mediated inhibition of cell migration.PubMedPubMedCentralCrossRef
88.•
Zhang X et al. Inhibition of cell growth and induction of apoptosis in ovarian carcinoma cell lines CaOV3 and SKOV3 by natural withanolide Withaferin A. Gynecol Oncol. 2012;124(3):606–12. Authors have shown WA mediated downregulation of Notch1 and 3 in ovarian cancer cells. This downregulation correlated with induction of apoptosis and cell cycle arrest.PubMedPubMedCentralCrossRef
Metadata
Title
Targeting Notch Signaling in Colorectal Cancer
Authors
Suman Suman
Trinath P. Das
Murali K. Ankem
Chendil Damodaran
Publication date
01-12-2014
Publisher
Springer US
Published in
Current Colorectal Cancer Reports / Issue 4/2014
Print ISSN: 1556-3790
Electronic ISSN: 1556-3804
DOI
https://doi.org/10.1007/s11888-014-0252-3

Other articles of this Issue 4/2014

Current Colorectal Cancer Reports 4/2014 Go to the issue

Translational Colorectal Oncology (Y Jiang, Section Editor)

Are NSAIDs Coming Back to Colorectal Cancer Therapy or Not?

Translational Colorectal Oncology (Y Jiang, Section Editor)

The Role of Predictive Molecular Biomarkers for the Treatment of Metastatic Colorectal Cancer

Molecular Biology (S Anant, Section Editor)

Targeting Cancer Stem Cells by Phytochemicals: a Multimodal Approach to Colorectal Cancer

Immunotherapy of Malignancy (R Kim, Section Editor)

Peptide Vaccines for Treatment of Colon Cancer: Have We Made Progress?

Immunotherapy of Malignancy (R Kim, Section Editor)

Dendritic Cell Cancer Vaccines for Treatment of Colon Cancer

Molecular Biology (S Anant, Section Editor)

Histone Demethylases in Colon Cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits